Ocular surface unit (OSU)

The ocular surface unit is an integrated functional system comprising the cornea, conjunctiva, and the overlying tear film, which work together to maintain optical clarity and protect the eye (Source: StatPearls, Anatomy, Eye, Ocular Surface). The tear film is a complex, trilayered structure consisting of lipids, an aqueous component, and mucins that provide lubrication, nutrients, and antimicrobial defense to the ocular surface (Source: TFOS DEWS II Definition and Classification Report). Dysfunction of this unit, often characterized by a loss of tear film homeostasis, leads to Dry Eye Disease (DED), a condition involving inflammation, hyperosmolarity, and potential damage to the corneal and conjunctival epithelium (Source: NIH, National Eye Institute). Pharmacological interventions typically target specific molecular pathways within this system, such as inhibiting inflammatory cytokines or stimulating the production of tear components, to restore the health and stability of the ocular surface (Source: PubMed). Because it encompasses multiple tissues and fluids, the ocular surface unit is viewed as a holistic therapeutic target in ophthalmology rather than a single molecular entity.

Other names

Ocular surfaceTear filmCorneal epitheliumConjunctival epitheliumOcular surface systemOcular surface unit

Drugs targeting the ocular surface unit act through various mechanisms: immunomodulation (e.g., Cyclosporine inhibits T-cell activation), integrin antagonism (e.g., Lifitegrast blocks LFA-1/ICAM-1 interaction), cholinergic stimulation (e.g., Varenicline activates the trigeminal parasympathetic pathway), and lipid layer supplementation (e.g., Perfluorohexyloctane reduces evaporation) (Source: FDA, PubMed).